ES2082887T3 - Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares. - Google Patents

Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.

Info

Publication number
ES2082887T3
ES2082887T3 ES91111124T ES91111124T ES2082887T3 ES 2082887 T3 ES2082887 T3 ES 2082887T3 ES 91111124 T ES91111124 T ES 91111124T ES 91111124 T ES91111124 T ES 91111124T ES 2082887 T3 ES2082887 T3 ES 2082887T3
Authority
ES
Spain
Prior art keywords
flupirtine
antiparkinsonians
combination
muscular spasms
combat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91111124T
Other languages
English (en)
Spanish (es)
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Juergen Prof Engel
Peter Dr Emig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2082887T3 publication Critical patent/ES2082887T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Medicines Containing Plant Substances (AREA)
ES91111124T 1990-07-14 1991-07-04 Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares. Expired - Lifetime ES2082887T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (en, 2012) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
ES2082887T3 true ES2082887T3 (es) 1996-04-01

Family

ID=25895002

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91111124T Expired - Lifetime ES2082887T3 (es) 1990-07-14 1991-07-04 Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
ES95101189T Expired - Lifetime ES2164111T3 (es) 1990-07-14 1991-07-04 Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95101189T Expired - Lifetime ES2164111T3 (es) 1990-07-14 1991-07-04 Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.

Country Status (30)

Country Link
US (2) US5162346A (en, 2012)
EP (2) EP0467164B1 (en, 2012)
KR (1) KR0182811B1 (en, 2012)
CN (1) CN1070700C (en, 2012)
AT (2) ATE206919T1 (en, 2012)
AU (1) AU634073B2 (en, 2012)
CA (1) CA2046943C (en, 2012)
CZ (1) CZ280879B6 (en, 2012)
DE (3) DE4122166A1 (en, 2012)
DK (2) DK0467164T3 (en, 2012)
EG (1) EG19814A (en, 2012)
ES (2) ES2082887T3 (en, 2012)
GR (1) GR3019179T3 (en, 2012)
HR (1) HRP920667B1 (en, 2012)
HU (1) HU206973B (en, 2012)
IE (1) IE74688B1 (en, 2012)
IL (1) IL98810A (en, 2012)
IN (1) IN172468B (en, 2012)
LT (1) LT3593B (en, 2012)
LV (1) LV10048B (en, 2012)
MC (1) MC2272A1 (en, 2012)
MX (1) MX9100160A (en, 2012)
NO (1) NO912758L (en, 2012)
NZ (1) NZ238940A (en, 2012)
PT (1) PT98291B (en, 2012)
RO (1) RO108220B1 (en, 2012)
RU (1) RU2070408C1 (en, 2012)
SI (1) SI9111227B (en, 2012)
SK (1) SK279567B6 (en, 2012)
ZA (1) ZA915466B (en, 2012)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9321574U1 (de) * 1992-03-11 2000-06-29 Asta Medica Ag, 01277 Dresden Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
PL354484A1 (en) * 1999-08-03 2004-01-26 Awd Pharma Gmbh & Co.Kg Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (de) * 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
EP4523687A3 (en) 2019-10-10 2025-05-21 Xenon Pharmaceuticals Inc. Solid state crystalline forms of a selective potassium channel modulator
BR112022008580A2 (pt) 2019-11-08 2022-08-09 Xenon Pharmaceuticals Inc Métodos para tratar transtornos depressivos
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
KR0182811B1 (ko) 1999-05-01
EP0659410A2 (de) 1995-06-28
DK0467164T3 (da) 1996-03-04
ATE206919T1 (de) 2001-11-15
DE59109222D1 (de) 2001-11-22
LTIP919A (en) 1995-03-27
IL98810A0 (en) 1992-07-15
CN1058716A (zh) 1992-02-19
CA2046943A1 (en) 1992-01-15
EG19814A (en) 1996-02-29
SI9111227A (en) 1995-06-30
EP0467164A2 (de) 1992-01-22
US5162346A (en) 1992-11-10
DE4122166A1 (de) 1992-01-16
HRP920667B1 (en) 1998-06-30
US5284861A (en) 1994-02-08
EP0659410A3 (de) 1995-10-25
HRP920667A2 (en) 1996-10-31
AU8040391A (en) 1992-01-16
CA2046943C (en) 1996-03-12
MC2272A1 (fr) 1993-06-23
HUT59313A (en) 1992-05-28
DE59107331D1 (de) 1996-03-14
LV10048A (lv) 1994-05-10
ZA915466B (en) 1992-04-29
LV10048B (en) 1995-06-20
KR920002147A (ko) 1992-02-28
IE74688B1 (en) 1997-07-30
IN172468B (en, 2012) 1993-08-14
GR3019179T3 (en) 1996-06-30
EP0467164A3 (en) 1992-04-15
MX9100160A (es) 1992-02-28
PT98291B (pt) 1999-01-29
HU206973B (en) 1993-03-01
CN1070700C (zh) 2001-09-12
RU2070408C1 (ru) 1996-12-20
DK0659410T3 (da) 2001-12-27
LT3593B (en) 1995-12-27
HU912359D0 (en) 1991-12-30
IE912451A1 (en) 1992-01-15
SK279567B6 (sk) 1999-01-11
AU634073B2 (en) 1993-02-11
ATE133564T1 (de) 1996-02-15
SI9111227B (sl) 2000-12-31
CZ280879B6 (cs) 1996-04-17
CS210191A3 (en) 1992-02-19
RO108220B1 (ro) 1994-03-31
NO912758D0 (no) 1991-07-12
NZ238940A (en) 1997-05-26
ES2164111T3 (es) 2002-02-16
PT98291A (pt) 1992-05-29
IL98810A (en) 1996-01-19
NO912758L (no) 1992-01-15
EP0659410B1 (de) 2001-10-17
EP0467164B1 (de) 1996-01-31

Similar Documents

Publication Publication Date Title
ES2082887T3 (es) Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
FI924305A0 (fi) N-alkyl-3-fenyl-3-(2-alkyltiofenoxi) propylaminer.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
BG101040A (en) Benzopyrans and their use as therapeutic agents
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
IT1237088B (it) N,n'-di-(trimetossibenzoil) piperazine 2-carbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
EP0210099A3 (en) Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease
MX9203508A (es) 1,7-difenil-3-metilaza -7-ciano-8-metilnonano para usarse en el tratamiento de enfermedades.
MX9606304A (es) Benzopiranos y uso como agentes terapeuticos.
FI906462A7 (fi) Terapiredskap foer muskler.
ES1026542Y (es) Dispositivo para realizar masaje muscular.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 467164

Country of ref document: ES